Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
RGNX similar filings
- 3 Jan 19 REGENXBIO Reports Continued Progress Across Programs inYear-End 2018 Corporate Update
- 7 Nov 18 Announces first subject dosed in RGX-121 Phase I/II clinical trial for MPS II
- 6 Nov 18 REGENXBIO could receive up to $180 million, including $40 million in guaranteed payments
- 29 Oct 18 Regulation FD Disclosure
- 10 Aug 18 Regenxbio Announces Pricing of Public Offering of Common Stock
- 8 Aug 18 Announces positive interim update from RGX-314 Phase I clinical trial for wet AMD
- 11 Jun 18 REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis
Filing view
External links